JPH0130807B2 - - Google Patents
Info
- Publication number
- JPH0130807B2 JPH0130807B2 JP59100727A JP10072784A JPH0130807B2 JP H0130807 B2 JPH0130807 B2 JP H0130807B2 JP 59100727 A JP59100727 A JP 59100727A JP 10072784 A JP10072784 A JP 10072784A JP H0130807 B2 JPH0130807 B2 JP H0130807B2
- Authority
- JP
- Japan
- Prior art keywords
- parts
- sodium fluoride
- talc
- matrix
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 65
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 34
- 239000011775 sodium fluoride Substances 0.000 claims description 32
- 235000013024 sodium fluoride Nutrition 0.000 claims description 32
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 30
- 239000004203 carnauba wax Substances 0.000 claims description 23
- 235000013869 carnauba wax Nutrition 0.000 claims description 23
- 239000000454 talc Substances 0.000 claims description 20
- 229910052623 talc Inorganic materials 0.000 claims description 20
- 239000011159 matrix material Substances 0.000 claims description 18
- 235000000346 sugar Nutrition 0.000 claims description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims description 15
- 235000012222 talc Nutrition 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims 3
- 239000003826 tablet Substances 0.000 description 33
- 238000011282 treatment Methods 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 12
- 239000001993 wax Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000020084 Bone disease Diseases 0.000 description 5
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 150000002222 fluorine compounds Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- -1 fluoride ions Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52201483A | 1983-08-11 | 1983-08-11 | |
| US522014 | 1983-08-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6042323A JPS6042323A (ja) | 1985-03-06 |
| JPH0130807B2 true JPH0130807B2 (fr) | 1989-06-22 |
Family
ID=24079076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59100727A Granted JPS6042323A (ja) | 1983-08-11 | 1984-05-21 | フツ化物錠剤とその製法 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS6042323A (fr) |
| CA (1) | CA1219219A (fr) |
| CH (1) | CH655851A5 (fr) |
| DE (1) | DE3343253A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2063033T3 (es) * | 1987-04-28 | 1995-01-01 | Boehringer Mannheim Gmbh | Empleo de igf-ii en el tratamiento de la enfermedades de los huesos. |
| MXPA05009469A (es) * | 2003-03-04 | 2005-12-12 | Nostrum Pharmaceuticals Inc | Formulacion de liberacion controlada que contiene un material hidrofobico como agente de liberacion prolongada. |
| CN103439377B (zh) * | 2013-08-13 | 2015-12-09 | 江苏大学 | 一种NaF释放的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2805977A (en) * | 1955-01-04 | 1957-09-10 | Smith Kline French Lab | Sustained release pharmaceutical preparation |
| DE2630326C2 (de) * | 1976-07-06 | 1983-07-21 | "Gebro" G. Broschek Kg, Chemisch-Pharmazeutische Fabrik, 6391 Fieberbrunn, Tirol | Präparat zur Behandlung der Osteoporose und seine Herstellung |
-
1983
- 1983-11-30 DE DE19833343253 patent/DE3343253A1/de active Granted
- 1983-12-14 CH CH6669/83A patent/CH655851A5/de not_active IP Right Cessation
-
1984
- 1984-01-05 CA CA000444788A patent/CA1219219A/fr not_active Expired
- 1984-05-21 JP JP59100727A patent/JPS6042323A/ja active Granted
Non-Patent Citations (4)
| Title |
|---|
| CHEMICAL ABSTRACTS=1974 * |
| CHEMICAL ABSTRACTS=1975 * |
| CHEMICAL ABSTRACTS=1976 * |
| CHEMICAL ABSTRACTS=1981 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3343253A1 (de) | 1985-02-21 |
| DE3343253C2 (fr) | 1989-07-20 |
| CA1219219A (fr) | 1987-03-17 |
| JPS6042323A (ja) | 1985-03-06 |
| CH655851A5 (de) | 1986-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69911240T2 (de) | Zusammensetzungen, enthaltend mikronisiertes eplerenon | |
| US5055306A (en) | Sustained-release formulations | |
| DE69820287T2 (de) | Pharmazeutische Zubereitung, die Chlodronat als Wirkstoff und silicifizierte mikrokristalline Cellulose als Exipienten umfasst | |
| TW576743B (en) | Extended release formulations of erythromycin derivatives | |
| DE4225730C2 (de) | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung | |
| US4904478A (en) | Slow-release sodium fluoride tablet and method for treatment of osteoporosis | |
| DE69837610T2 (de) | Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird in verzögert freigesetzter form und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung | |
| IE53543B1 (en) | New oral dipyridamole preparations | |
| JPH0122245B2 (fr) | ||
| CZ287378B6 (en) | Pharmaceutical preparation containing fluoxetine and process for preparing thereof | |
| HU220075B (hu) | Hosszan tartó hatóanyag-leadású morfintartalmú gyógyszerkészítmények és eljárás ezek előállítására | |
| JPS63107917A (ja) | イブプロフエン徐放性製剤およびその製造方法 | |
| AU748359B2 (en) | Controlled-release formulations | |
| EP1509207B1 (fr) | Composition pharmaceutique à base d'oxcarbazepine, à libération retard du principe actif | |
| DE69929703T2 (de) | Neue orale formulierungen für 5-ht4 agonisten oder antagonisten | |
| JP2008518914A (ja) | アセトアミノフェン、カフェインおよび所望によりアスピリンを、吸収を増強するためのアルカリ性物質と共に含む組成物 | |
| WO2006115770A2 (fr) | Preparations pharmaceutiques d'olazanpine en comprimes a desintegration orale | |
| DE60225686T2 (de) | Paracetamol enthaltende tablette | |
| US5650168A (en) | Tablet with improved bioavailability containing dichloromethylenediphosphonic acid as the active substance | |
| WO2000037078A1 (fr) | Association de cerivastatine et de fibrates | |
| CN109010361B (zh) | 碳酸钙维生素d3制剂及其制备方法 | |
| US4859467A (en) | Sustained release fluoride composition | |
| DE60013466T2 (de) | Im mund zerfallende zusammensetzung mit mirtazapin | |
| US5013728A (en) | Composition for treating osteoporosis and hormonal imbalance | |
| CA1099641A (fr) | Traduction non-disponible |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |